• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cross Country Healthcare Announces Fourth Quarter and Full Year 2025 Financial Results

    3/4/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary
    Get the next $CCRN alert in real time by email

    Cross Country Healthcare, Inc. (the "Company," "Cross Country," "we," "us," and "our") (NASDAQ:CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2025.

    SELECTED FINANCIAL INFORMATION:

    Dollars are in thousands, except per share amounts

    Q4 2025

    Variance

    Q4 2025 vs

    Q4 2024

    Variance

    Q4 2025 vs

    Q3 2025

    Full Year 2025

    Variance

    2025 vs

    2024

    Revenue

    $

    236,761

     

     

     

    (24

    )

    %

     

    (5

    )

    %

    $

    1,054,293

     

     

     

    (22

    )

    %

    Gross profit margin*

     

    20.3

     

    %

     

    30

     

    bps

     

    (10

    )

    bps

     

    20.3

     

    %

     

    (10

    )

    bps

    Net loss attributable to common stockholders

    $

    (82,929

    )

     

     

    (2,110

    )

    %

     

    (1,637

    )

    %

    $

    (94,852

    )

     

     

    (552

    )

    %

    Diluted EPS

    $

    (2.56

    )

     

    $

    (2.44

    )

     

    $

    (2.41

    )

     

    $

    (2.93

    )

     

    $

    (2.49

    )

     

    Adjusted EBITDA*

    $

    4,067

     

     

     

    (56

    )

    %

     

    (38

    )

    %

    $

    26,801

     

     

     

    (45

    )

    %

    Adjusted EBITDA margin*

     

    1.7

     

    %

     

    (130

    )

    bps

     

    (90

    )

    bps

     

    2.5

     

    %

     

    (120

    )

    bps

    Adjusted EPS*

    $

    (0.06

    )

     

    $

    (0.10

    )

     

    $

    (0.09

    )

     

    $

    0.02

     

     

    $

    (0.44

    )

     

    Cash flows provided by operations

    $

    18,239

     

     

     

    (25

    )

    %

     

    (9

    )

    %

    $

    48,251

     

     

     

    (60

    )

    %

    * Represents amounts that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP) and are referred to as non-GAAP measures. Please refer to the accompanying discussion below of how these non-GAAP financial measures are calculated and used under "Non-GAAP Financial Measures" and the tables reconciling these measures to the closest GAAP measure.

    Fourth Quarter and Full Year Business Highlights

    • 735 facilities, over 5,900 users, and 5.7 million hours processed in 2025 with Intellify®
    • 95% of MSP and vendor neutral clients are now live on Intellify®
    • Continued positive cash flow from operations for the quarter and year
    • Strong balance sheet with $109 million of cash on hand and no debt as of December 31, 2025
    • Repurchased over 800,000 shares, or 2.5% of common stock outstanding in the fourth quarter
    • Reduced US headcount by 21% in 2025, driving cost savings through our India center of excellence

    "In addition to a challenging market backdrop, particularly for travel staffing, our performance last year was certainly impacted by the protracted merger process. As we enter 2026 unencumbered and laser focused, I'm encouraged, not just by the signs of an improving market, but also by the returns from the investments and actions we have taken already," said Kevin C. Clark, Co-Founder, Chairman, and CEO. He continued, "The engine of our growth is centered around our proprietary technology Intellify® and along with strategic investments in revenue producers and the leverage of our robust balance sheet, I believe we will see sequential progression throughout 2026. Our goal is to exit the year at a revenue run-rate north of $1 billion and a profit margin between four and five percent."

    Fourth quarter consolidated revenue was $236.8 million, a decrease of 24% year-over-year and 5% sequentially. Consolidated gross profit margin was 20.3%, up 30 basis points year-over-year and down 10 basis points sequentially. Net loss attributable to common stockholders was $82.9 million, as compared to a net loss of $3.8 million in the prior year and a net loss of $4.8 million in the prior quarter. The current period net loss was primarily driven by a goodwill and trade name impairment charge of $77.9 million as well as a $29.6 million valuation allowance against deferred tax assets. The goodwill impairment assessment and related charge was primarily triggered by the fourth quarter decline in the Company's equity market capitalization following the termination of the Aya Merger Agreement.

    Diluted earnings per share (EPS) was a net loss of $2.56, as compared to a net loss of $0.12 in the prior year and a net loss of $0.15 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $4.1 million, or 1.7% of revenue, as compared with $9.3 million, or 3.0% of revenue, in the prior year, and $6.5 million, or 2.6% of revenue, in the prior quarter. Adjusted EPS was $(0.06), as compared to $0.04 in the prior year and $0.03 in the prior quarter.

    For the year ended December 31, 2025, consolidated revenue was $1.1 billion, a decrease of 22% year-over-year. Consolidated gross profit margin was 20.3%, down 10 basis points year-over-year. Net loss attributable to common stockholders was $94.9 million, or $2.93 per diluted share, as compared to a net loss of $14.6 million, or $0.44 per diluted share, in the prior year. Adjusted EBITDA was $26.8 million, or 2.5% of revenue, as compared to $49.1 million, or 3.7% of revenue, in the prior year. Adjusted EPS was $0.02, as compared to $0.46 in the prior year.

    Quarterly Business Segment Highlights

    Nurse and Allied Staffing

    Revenue was $194.2 million, a decrease of 24% year-over-year and 4% sequentially. Contribution income was $12.6 million, as compared to $20.3 million in the prior year and $14.2 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis was 6,318, as compared with 7,621 in the prior year and 6,371 in the prior quarter. Revenue per FTE per day was $333, as compared to $363 in the prior year and $343 in the prior quarter.

    Physician Staffing

    Revenue was $42.5 million, a decrease of 20% year-over-year and 12% sequentially. Contribution income was $3.3 million, as compared to $3.5 million in the prior year and $4.3 million in the prior quarter. Total days filled were 18,599, as compared with 25,427 in the prior year and 20,695 in the prior quarter. Revenue per day filled was $2,286, as compared with $2,085 in the prior year and $2,324 in the prior quarter.

    Cash Flow and Balance Sheet Highlights

    Net cash provided by operating activities for the three months ended December 31, 2025 was $18.2 million, as compared to $24.2 million for the three months ended December 31, 2024 and $20.1 million for the three months ended September 30, 2025. For the year ended December 31, 2025, net cash provided by operating activities was $48.3 million, as compared to $120.1 million in the prior year.

    In connection with its termination of the Aya Merger Agreement, a termination fee of $20.0 million was paid to the Company during the fourth quarter. The Company recorded the Aya termination fee within operating cash flows for the three months and year ended December 31, 2025. The net cash operating inflows associated with the Aya Merger were $14.2 million and $5.8 million for the three months and year ended December 31, 2025, respectively.

    During the fourth quarter, the Company repurchased a total of 0.8 million shares of its common stock for an aggregate price of $6.5 million, at an average market price of $8.10 per share. As of December 31, 2025, the Company had 31.7 million unrestricted shares outstanding and $34.0 million remaining for share repurchase.

    At December 31, 2025, the Company had $108.7 million in cash and cash equivalents with no debt outstanding. There were no borrowings drawn under its revolving senior secured asset-based credit facility (ABL). As of December 31, 2025, borrowing base availability under the ABL was $114.6 million, with $96.3 million of availability net of $18.3 million of letters of credit.

    Outlook for First Quarter 2026

    The guidance below applies to management's expectations for the first quarter of 2026.

     

    Q1 2026 Range

     

    Year-over-Year

     

    Sequential

    Change

     

    Change

     

    Revenue

    $235 million - $240 million

     

    (20)% - (18)%

     

    (1)% - 1%

     

     

     

     

     

     

    Adjusted EBITDA*

    $4.0 million - $5.0 million

     

    (54)% - (42)%

     

    (2)% - 23%

     

     

     

     

     

     

    Adjusted EPS*

    $(0.06) - $(0.04)

     

    $(0.12) - $(0.10)

     

    $0 - $0.02

    * Refer to discussion of non-GAAP financial measures and the reconciliation tables below.

    The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases.

    INVITATION TO CONFERENCE CALL

    The Company will hold its quarterly conference call on Wednesday, March 4, 2026, at 5:00 P.M. Eastern Time to discuss its fourth quarter and full year 2025 financial results. This call will be webcast live and can be accessed at the Company's website at ir.crosscountry.com or by dialing 800-369-2163 from anywhere in the U.S. or by dialing 773-756-4715 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from March 4th through March 18th on the Company's website and a replay of the conference call will be available by telephone by calling 866-360-7724 from anywhere in the U.S. or 203-369-0176 from non-U.S. locations - Passcode: 2047.

    ABOUT CROSS COUNTRY HEALTHCARE

    Cross Country Healthcare, Inc. (NASDAQ:CCRN) is a healthcare workforce solutions company delivering an AI-powered digital platform and advisory services, backed by nearly 40 years of healthcare labor expertise, to help health systems optimize and sustain their entire labor ecosystem.

    Through Intellify®, Cross Country's cloud-based workforce management and vendor management system, health systems gain clear visibility across internal and contingent labor. Intellify® integrates with core hospital systems and brings all service lines, including non-clinical, nursing, allied health, and locums, into one centralized view. Powered by real-time analytics and AI-driven insights, Intellify® helps leaders make smarter workforce decisions, streamline operations, reduce labor costs, improve flexibility, and support high-quality outcomes.

    Copies of this and other press releases, as well as additional information about the Company, can be accessed online at ir.crosscountry.com. Stockholders and prospective investors can also register to automatically receive the Company's press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

    NON-GAAP FINANCIAL MEASURES

    This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, adjusted EBITDA margin, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes such non-GAAP financial measures are useful to investors when evaluating the Company's performance, as such non-GAAP financial measures exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

    In addition, forward-looking adjusted EBITDA and adjusted EPS for the first quarter of 2026 exclude potential charges or gains that may be recorded during the fiscal year, including among other things, the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases. We have not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of our financial performance.

    FORWARD LOOKING STATEMENTS

    This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact, including statements relating to our future results (including business trends), may be deemed to be forward-looking statements. All such forward-looking statements are intended to provide management's current expectations for the future of the Company based on current expectations and assumptions relating to the Company's business, the economy, and other future conditions. Forward-looking statements generally can be identified through the use of words such as "believes," "anticipates," "may," "should," "will," "plans," "projects," "expects," "expectations," "estimates," "forecasts," "predicts," "targets," "prospects," "strategy," "signs," and other words of similar meaning in connection with the discussion of future performance, plans, actions, or events. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties, and changes in circumstances that are difficult to predict. Such risks and uncertainties include, among others: (i) worldwide economic or political changes that affect the markets that the Company's businesses serve, which could have an effect on demand for the Company's services and impact the Company's profitability, (ii) effects from global pandemics, epidemics, or other public health crises, (iii) changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement and customer needs, (iv) disruptions in the global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, including tariffs and trade restrictions, foreign currency volatility, swings in consumer confidence and spending, and the overall macroeconomic environment, (v) the functioning of our information systems and the effect of cyber security risks and cyber incidents on our business, (vi) demand for the healthcare services that we provide, both nationally and in the regions in which we operate, (vii) leadership transitions and retention of key employees, (viii) our ability to attract and retain qualified nurses, physicians, and other healthcare personnel, (ix) costs and availability of short-term housing for our travel healthcare professionals, (x) the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, and (xi) outcomes of regulatory and legal proceedings, claims, and investigations. Accordingly, actual results may differ materially from those contemplated by these forward-looking statements. Investors, therefore, are cautioned against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the SEC, including the risks and uncertainties identified in Part I, Item 1A - Risk Factors of the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and in the Company's other filings with the SEC. The list of factors is not intended to be exhaustive.

    These forward-looking statements speak only as of the date of this press release. Except as may be required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement made in this press release or that may from time to time be made by or on behalf of the Company.

    Cross Country Healthcare, Inc.

    Consolidated Statements of Operations

    (Unaudited, amounts in thousands, except per share data)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

    September 30,

     

    December 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2025

     

     

     

    2024

     

     

     

     

     

    Revenue from services

    $

    236,761

     

     

    $

    309,940

     

     

    $

    250,052

     

     

    $

    1,054,293

     

     

    $

    1,344,004

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

    Direct operating expenses

     

    188,779

     

     

     

    247,948

     

     

     

    199,125

     

     

     

    840,722

     

     

     

    1,069,752

     

    Selling, general and administrative expenses

     

    51,250

     

     

     

    55,573

     

     

     

    46,894

     

     

     

    200,680

     

     

     

    233,377

     

    Credit loss expense (credit)

     

    355

     

     

     

    (228

    )

     

     

    (861

    )

     

     

    (441

    )

     

     

    21,432

     

    Depreciation and amortization

     

    3,833

     

     

     

    4,341

     

     

     

    4,088

     

     

     

    16,794

     

     

     

    18,200

     

    Acquisition and integration-related (income) costs

     

    (15,577

    )

     

     

    4,216

     

     

     

    4,147

     

     

     

    (3,394

    )

     

     

    4,219

     

    Restructuring costs

     

    1,327

     

     

     

    281

     

     

     

    1,530

     

     

     

    3,746

     

     

     

    4,333

     

    Legal and other losses (gains)

     

    548

     

     

     

    (928

    )

     

     

    1,102

     

     

     

    2,749

     

     

     

    6,668

     

    Impairment charges

     

    77,851

     

     

     

    2,170

     

     

     

    —

     

     

     

    77,851

     

     

     

    2,888

     

    Total operating expenses

     

    308,366

     

     

     

    313,373

     

     

     

    256,025

     

     

     

    1,138,707

     

     

     

    1,360,869

     

    Loss from operations

     

    (71,605

    )

     

     

    (3,433

    )

     

     

    (5,973

    )

     

     

    (84,414

    )

     

     

    (16,865

    )

    Other expenses (income):

     

     

     

     

     

     

     

     

     

    Interest expense

     

    568

     

     

     

    608

     

     

     

    556

     

     

     

    2,216

     

     

     

    2,188

     

    Interest income

     

    (882

    )

     

     

    (535

    )

     

     

    (864

    )

     

     

    (3,129

    )

     

     

    (2,050

    )

    Other (income) expense, net

     

    (46

    )

     

     

    408

     

     

     

    (28

    )

     

     

    9

     

     

     

    (605

    )

    Loss before income taxes

     

    (71,245

    )

     

     

    (3,914

    )

     

     

    (5,637

    )

     

     

    (83,510

    )

     

     

    (16,398

    )

    Income tax expense (benefit)

     

    11,684

     

     

     

    (161

    )

     

     

    (863

    )

     

     

    11,342

     

     

     

    (1,842

    )

    Net loss attributable to common stockholders

    $

    (82,929

    )

     

    $

    (3,753

    )

     

    $

    (4,774

    )

     

    $

    (94,852

    )

     

    $

    (14,556

    )

     

     

     

     

     

     

     

     

     

     

    Net loss per share attributable to common stockholders - Basic

    $

    (2.56

    )

     

    $

    (0.12

    )

     

    $

    (0.15

    )

     

    $

    (2.93

    )

     

    $

    (0.44

    )

     

     

     

     

     

     

     

     

     

     

    Net loss per share attributable to common stockholders - Diluted

    $

    (2.56

    )

     

    $

    (0.12

    )

     

    $

    (0.15

    )

     

    $

    (2.93

    )

     

    $

    (0.44

    )

     

     

     

     

     

     

     

     

     

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

     

     

     

    Basic

     

    32,334

     

     

     

    32,338

     

     

     

    32,524

     

     

     

    32,409

     

     

     

    33,379

     

    Diluted

     

    32,334

     

     

     

    32,338

     

     

     

    32,524

     

     

     

    32,409

     

     

     

    33,379

    Cross Country Healthcare, Inc.

    Reconciliation of Non-GAAP Financial Measures

    (Unaudited, amounts in thousands)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

    September 30,

     

    December 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2025

     

     

     

    2024

     

    Adjusted EBITDA:a

     

     

     

     

     

     

     

     

     

    Net loss attributable to common stockholders

    $

    (82,929

    )

     

    $

    (3,753

    )

     

    $

    (4,774

    )

     

    $

    (94,852

    )

     

    $

    (14,556

    )

    Interest expense

     

    568

     

     

     

    608

     

     

     

    556

     

     

     

    2,216

     

     

     

    2,188

     

    Income tax expense (benefit)b

     

    11,684

     

     

     

    (161

    )

     

     

    (863

    )

     

     

    11,342

     

     

     

    (1,842

    )

    Depreciation and amortization

     

    3,833

     

     

     

    4,341

     

     

     

    4,088

     

     

     

    16,794

     

     

     

    18,200

     

    Acquisition and integration-related (income) costsc

     

    (15,577

    )

     

     

    4,216

     

     

     

    4,147

     

     

     

    (3,394

    )

     

     

    4,219

     

    Restructuring costsd

     

    1,327

     

     

     

    281

     

     

     

    1,530

     

     

     

    3,746

     

     

     

    4,333

     

    Severance costs - executive transitione

     

    6,035

     

     

     

    —

     

     

     

    —

     

     

     

    6,035

     

     

     

    —

     

    Legal, bankruptcy, and other losses (gains)f

     

    548

     

     

     

    (928

    )

     

     

    1,102

     

     

     

    2,749

     

     

     

    26,041

     

    Impairment chargesg

     

    77,851

     

     

     

    2,170

     

     

     

    —

     

     

     

    77,851

     

     

     

    2,888

     

    Loss on disposal of fixed assets

     

    57

     

     

     

    86

     

     

     

    —

     

     

     

    62

     

     

     

    86

     

    Gain on lease termination

     

    (121

    )

     

     

    —

     

     

     

    —

     

     

     

    (121

    )

     

     

    —

     

    Interest income

     

    (882

    )

     

     

    (535

    )

     

     

    (864

    )

     

     

    (3,129

    )

     

     

    (2,050

    )

    Other expense (income), net

     

    18

     

     

     

    322

     

     

     

    (28

    )

     

     

    68

     

     

     

    (691

    )

    Equity compensation

     

    1,117

     

     

     

    1,698

     

     

     

    766

     

     

     

    4,071

     

     

     

    6,025

     

    System conversion costsh

     

    538

     

     

     

    926

     

     

     

    864

     

     

     

    3,363

     

     

     

    4,232

     

    Adjusted EBITDAa

    $

    4,067

     

     

    $

    9,271

     

     

    $

    6,524

     

     

    $

    26,801

     

     

    $

    49,073

     

    Adjusted EBITDA margina

     

    1.7

    %

     

     

    3.0

    %

     

     

    2.6

    %

     

     

    2.5

    %

     

     

    3.7

    %

     

     

     

     

     

     

     

     

     

     

    Adjusted EPS:i

     

     

     

     

     

     

     

     

     

    Numerator:

     

     

     

     

     

     

     

     

     

    Net loss attributable to common stockholders

    $

    (82,929

    )

     

    $

    (3,753

    )

     

    $

    (4,774

    )

     

    $

    (94,852

    )

     

    $

    (14,556

    )

    Non-GAAP adjustments - pretax:

     

     

     

     

     

     

     

     

     

    Acquisition and integration-related (income) costsc

     

    (15,577

    )

     

     

    4,216

     

     

     

    4,147

     

     

     

    (3,394

    )

     

     

    4,219

     

    Restructuring costsd

     

    1,327

     

     

     

    281

     

     

     

    1,530

     

     

     

    3,746

     

     

     

    4,333

     

    Severance costs - executive transitione

     

    6,035

     

     

     

    —

     

     

     

    —

     

     

     

    6,035

     

     

     

    —

     

    Legal, bankruptcy, and other losses (gains)f

     

    548

     

     

     

    (928

    )

     

     

    1,102

     

     

     

    2,749

     

     

     

    26,041

     

    Impairment chargesg

     

    77,851

     

     

     

    2,170

     

     

     

    —

     

     

     

    77,851

     

     

     

    2,888

     

    Other expense (income), net

     

    —

     

     

     

    311

     

     

     

    —

     

     

     

    —

     

     

     

    (804

    )

    System conversion costsh

     

    538

     

     

     

    926

     

     

     

    864

     

     

     

    3,363

     

     

     

    4,232

     

    Nonrecurring income tax adjustmentsj

     

    29,449

     

     

     

    —

     

     

     

    —

     

     

     

    29,449

     

     

     

    —

     

    Tax impact of non-GAAP adjustments

     

    (19,296

    )

     

     

    (1,843

    )

     

     

    (2,011

    )

     

     

    (24,456

    )

     

     

    (10,867

    )

    Adjusted net income attributable to common stockholders - non-GAAP

    $

    (2,054

    )

     

    $

    1,380

     

     

    $

    858

     

     

    $

    491

     

     

    $

    15,486

     

     

     

     

     

     

     

     

     

     

     

    Denominator:

     

     

     

     

     

     

     

     

     

    Weighted average common shares - basic, GAAP

     

    32,334

     

     

     

    32,338

     

     

     

    32,524

     

     

     

    32,409

     

     

     

    33,379

     

    Dilutive impact of share-based payments

     

    77

     

     

     

    68

     

     

     

    —

     

     

     

    98

     

     

     

    133

     

    Adjusted weighted average common shares - diluted, non-GAAP

    32,411

     

     

    32,406

     

     

    32,524

     

     

    32,507

     

     

    33,512

     

     

     

     

     

     

     

     

     

     

     

    Reconciliation:

     

     

     

     

     

     

     

     

     

    Diluted EPS, GAAP

    $

    (2.56

    )

     

    $

    (0.12

    )

     

    $

    (0.15

    )

     

    $

    (2.93

    )

     

    $

    (0.44

    )

    Non-GAAP adjustments - pretax:

     

     

     

     

     

     

     

     

     

    Acquisition and integration-related (income) costsc

     

    (0.48

    )

     

     

    0.13

     

     

     

    0.13

     

     

     

    (0.10

    )

     

     

    0.13

     

    Restructuring costsd

     

    0.04

     

     

     

    0.01

     

     

     

    0.05

     

     

     

    0.12

     

     

     

    0.13

     

    Severance costs - executive transitione

     

    0.18

     

     

     

    —

     

     

     

    —

     

     

     

    0.18

     

     

     

    —

     

    Legal, bankruptcy, and other losses (gains)f

     

    0.02

     

     

     

    (0.03

    )

     

     

    0.03

     

     

     

    0.08

     

     

     

    0.77

     

    Impairment chargesg

     

    2.41

     

     

     

    0.07

     

     

     

    —

     

     

     

    2.41

     

     

     

    0.09

     

    Other expense (income),net

     

    —

     

     

     

    0.01

     

     

     

    —

     

     

     

    —

     

     

     

    (0.02

    )

    System conversion costsh

     

    0.02

     

     

     

    0.03

     

     

     

    0.03

     

     

     

    0.11

     

     

     

    0.13

     

    Nonrecurring income tax adjustmentsj

     

    0.91

     

     

     

    —

     

     

     

    —

     

     

     

    0.91

     

     

     

    —

     

    Tax impact of non-GAAP adjustments

     

    (0.60

    )

     

     

    (0.06

    )

     

     

    (0.06

    )

     

     

    (0.76

    )

     

     

    (0.33

    )

    Adjustment for change in dilutive shares

    —

     

     

    —

     

     

    —

     

     

    —

     

     

    —

     

    Adjusted EPS, non-GAAPi

    $

    (0.06

    )

     

    $

    0.04

     

     

    $

    0.03

     

     

    $

    0.02

     

     

    $

    0.46

     

    Cross Country Healthcare, Inc.

    Consolidated Balance Sheets

    (Unaudited, amounts in thousands)

     

     

    December 31,

     

    December 31,

     

     

    2025

     

     

     

    2024

     

     

     

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    108,738

     

     

    $

    81,633

     

    Accounts receivable, net

     

    167,512

     

     

     

    223,238

     

    Income taxes receivable

     

    3,594

     

     

     

    10,389

     

    Prepaid expenses

     

    7,561

     

     

     

    7,848

     

    Insurance recovery receivable

     

    4,851

     

     

     

    9,255

     

    Other current assets

     

    1,333

     

     

     

    2,637

     

    Total current assets

     

    293,589

     

     

     

    335,000

     

    Property and equipment, net

     

    27,775

     

     

     

    28,850

     

    Operating lease right-of-use assets

     

    2,206

     

     

     

    2,468

     

    Goodwill

     

    63,803

     

     

     

    135,060

     

    Other intangible assets, net

     

    27,635

     

     

     

    42,186

     

    Deferred tax assets

     

    —

     

     

     

    8,104

     

    Insurance recovery receivable

     

    14,859

     

     

     

    20,928

     

    Cloud computing

     

    14,028

     

     

     

    10,846

     

    Deferred compensation asset

     

    2,938

     

     

     

    2,889

     

    Other assets

     

    2,118

     

     

     

    2,920

     

    Total assets

    $

    448,951

     

     

    $

    589,251

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and accrued expenses

    $

    46,034

     

     

    $

    64,946

     

    Accrued compensation and benefits

     

    28,378

     

     

     

    47,646

     

    Operating lease liabilities

     

    1,163

     

     

     

    2,089

     

    Earnout liability

     

    —

     

     

     

    4,411

     

    Other current liabilities

     

    2,181

     

     

     

    1,310

     

    Total current liabilities

     

    77,756

     

     

     

    120,402

     

    Operating lease liabilities

     

    1,155

     

     

     

    1,782

     

    Deferred tax liabilities

     

    2,522

     

     

     

    566

     

    Accrued claims

     

    30,028

     

     

     

    34,425

     

    Uncertain tax positions

     

    10,427

     

     

     

    10,117

     

    Deferred compensation liability

     

    2,590

     

     

     

    2,926

     

    Other liabilities

     

    1,651

     

     

     

    74

     

    Total liabilities

     

    126,129

     

     

     

    170,292

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

    Common stock

     

    3

     

     

     

    3

     

    Additional paid-in capital

     

    201,172

     

     

     

    202,338

     

    Accumulated other comprehensive loss

     

    (1,560

    )

     

     

    (1,441

    )

    Retained earnings

     

    123,207

     

     

     

    218,059

     

    Total stockholders' equity

     

    322,822

     

     

     

    418,959

     

    Total liabilities and stockholders' equity

    $

    448,951

     

     

    $

    589,251

     

    Cross Country Healthcare, Inc.

    Segment Datak

    (Unaudited, amounts in thousands)

     

     

    Three Months Ended

     

    Year-over-Year

     

    Sequential

     

    December 31,

    % of

     

    December 31,

    % of

     

    September 30,

    % of

     

    % change

     

    % change

     

     

    2025

     

    Total

     

     

    2024

     

    Total

     

     

    2025

     

    Total

     

    Fav (Unfav)

     

    Fav (Unfav)

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services:

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    194,238

     

    82

    %

     

    $

    256,929

     

    83

    %

     

    $

    201,950

     

    81

    %

     

    (24

    )%

     

    (4

    )%

    Physician Staffing

     

    42,523

     

    18

    %

     

     

    53,011

     

    17

    %

     

     

    48,102

     

    19

    %

     

    (20

    )%

     

    (12

    )%

     

    $

    236,761

     

    100

    %

     

    $

    309,940

     

    100

    %

     

    $

    250,052

     

    100

    %

     

    (24

    )%

     

    (5

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Contribution income:l

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    12,552

     

     

     

    $

    20,347

     

     

     

    $

    14,230

     

     

     

    (38

    )%

     

    (12

    )%

    Physician Staffing

     

    3,310

     

     

     

     

    3,549

     

     

     

     

    4,320

     

     

     

    (7

    )%

     

    (23

    )%

     

     

    15,862

     

     

     

     

    23,896

     

     

     

     

    18,550

     

     

     

    (34

    )%

     

    (14

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Corporate overheadm

     

    19,485

     

     

     

     

    17,249

     

     

     

     

    13,656

     

     

     

    (13

    )%

     

    (43

    )%

    Depreciation and amortization

     

    3,833

     

     

     

     

    4,341

     

     

     

     

    4,088

     

     

     

    12

    %

     

    6

    %

    Restructuring costsd

     

    1,327

     

     

     

     

    281

     

     

     

     

    1,530

     

     

     

    (372

    )%

     

    13

    %

    Legal and other losses (gains)n

     

    548

     

     

     

     

    (928

    )

     

     

     

    1,102

     

     

     

    (159

    )%

     

    50

    %

    Impairment chargesg

     

    77,851

     

     

     

     

    2,170

     

     

     

     

    —

     

     

     

    NM

     

     

    (100.0

    )%

    Acquisition and integration-related (income) costsc

     

    (15,577

    )

     

     

     

    4,216

     

     

     

     

    4,147

     

     

     

    469

    %

     

    476

    %

    Loss from operations

    $

    (71,605

    )

     

     

    $

    (3,433

    )

     

     

    $

    (5,973

    )

     

     

    NM

     

     

    NM

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Year Ended

     

     

     

     

    Year-over-Year

     

     

     

    December 31,

    % of

     

    December 31,

    % of

     

     

     

     

    % change

     

     

     

     

    2025

     

    Total

     

     

    2024

     

    Total

     

     

     

     

    Fav (Unfav)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services:

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    862,784

     

    82

    %

     

    $

    1,145,419

     

    85

    %

     

     

     

     

    (25

    )%

     

     

    Physician Staffing

     

    191,509

     

    18

    %

     

     

    198,585

     

    15

    %

     

     

     

     

    (4

    )%

     

     

     

    $

    1,054,293

     

    100

    %

     

    $

    1,344,004

     

    100

    %

     

     

     

     

    (22

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Contribution income:l

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing

    $

    57,913

     

     

     

    $

    72,601

     

     

     

     

     

     

    (20

    )%

     

     

    Physician Staffing

     

    16,236

     

     

     

     

    15,349

     

     

     

     

     

     

    6

    %

     

     

     

     

    74,149

     

     

     

     

    87,950

     

     

     

     

     

     

    (16

    )%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Corporate overheadm

     

    60,817

     

     

     

     

    68,507

     

     

     

     

     

     

    11

    %

     

     

    Depreciation and amortization

     

    16,794

     

     

     

     

    18,200

     

     

     

     

     

     

    8

    %

     

     

    Restructuring costsd

     

    3,746

     

     

     

     

    4,333

     

     

     

     

     

     

    14

    %

     

     

    Legal and other lossesn

     

    2,749

     

     

     

     

    6,668

     

     

     

     

     

     

    59

    %

     

     

    Impairment chargesg

     

    77,851

     

     

     

     

    2,888

     

     

     

     

     

     

    NM

     

     

     

    Acquisition and integration-related income (costs)c

     

    (3,394

    )

     

     

     

    4,219

     

     

     

     

     

     

    180

    %

     

     

    Loss from operations

    $

    (84,414

    )

     

     

    $

    (16,865

    )

     

     

     

     

     

    (401

    )%

     

     

     

    NM - Not meaningful

    Cross Country Healthcare, Inc.

    Summary Condensed Consolidated Statements of Cash Flows

    (Unaudited, amounts in thousands)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

    Year Ended

     

    December 31,

     

     

    December 31,

     

     

    September 30,

     

     

    December 31,

     

    December 31,

     

     

    2025

     

     

     

     

    2024

     

     

     

     

    2025

     

     

     

     

    2025

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net cash provided by operating activities

    $

    18,239

     

     

     

    $

    24,234

     

     

     

    $

    20,114

     

     

     

    $

    48,251

     

     

    $

    120,116

     

    Net cash used in investing activities

     

    (2,117

    )

     

     

     

    (2,531

    )

     

     

     

    (2,191

    )

     

     

     

    (8,161

    )

     

     

    (8,714

    )

    Net cash used in financing activities

     

    (6,519

    )

     

     

     

    (4,077

    )

     

     

     

    (6

    )

     

     

     

    (13,006

    )

     

     

    (46,849

    )

    Effect of exchange rate changes on cash

     

    3

     

     

     

     

    (14

    )

     

     

     

    22

     

     

     

     

    21

     

     

     

    (14

    )

    Change in cash and cash equivalents

     

    9,606

     

     

     

     

    17,612

     

     

     

     

    17,939

     

     

     

     

    27,105

     

     

     

    64,539

     

    Cash and cash equivalents at beginning of period

     

    99,132

     

     

     

     

    64,021

     

     

     

     

    81,193

     

     

     

     

    81,633

     

     

     

    17,094

     

    Cash and cash equivalents at end of period

    $

    108,738

     

     

     

    $

    81,633

     

     

     

    $

    99,132

     

     

     

    $

    108,738

     

     

    $

    81,633

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Cross Country Healthcare, Inc.

    Other Financial Data

    (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

    Year Ended

     

    December 31,

     

     

    December 31,

     

     

    September 30,

     

     

    December 31,

     

    December 31,

     

     

    2025

     

     

     

     

    2024

     

     

     

     

    2025

     

     

     

     

    2025

     

     

     

    2024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue from services

    $

    236,761

     

     

     

    $

    309,940

     

     

     

    $

    250,052

     

     

     

    $

    1,054,293

     

     

    $

    1,344,004

     

    Less: Direct operating expenses

     

    188,779

     

     

     

     

    247,948

     

     

     

     

    199,125

     

     

     

     

    840,722

     

     

     

    1,069,752

     

    Gross profit

    $

    47,982

     

     

     

    $

    61,992

     

     

     

    $

    50,927

     

     

     

    $

    213,571

     

     

    $

    274,252

     

    Consolidated gross profit margino

     

    20.3

    %

     

     

     

    20.0

    %

     

     

     

    20.4

    %

     

     

     

    20.3

    %

     

     

    20.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Nurse and Allied Staffing statistical data:

     

     

     

     

     

     

     

     

     

     

     

     

    FTEsp

     

    6,318

     

     

     

     

    7,621

     

     

     

     

    6,371

     

     

     

     

    6,784

     

     

     

    8,205

     

    Average Nurse and Allied Staffing revenue per FTE per dayq

    $

    333

     

     

     

    $

    363

     

     

     

    $

    343

     

     

     

    $

    346

     

     

    $

    378

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Physician Staffing statistical data:

     

     

     

     

     

     

     

     

     

     

     

     

    Days filledr

     

    18,599

     

     

     

     

    25,427

     

     

     

     

    20,695

     

     

     

     

    84,213

     

     

     

    97,888

     

    Revenue per day filleds

    $

    2,286

     

     

     

    $

    2,085

     

     

     

    $

    2,324

     

     

     

    $

    2,274

     

     

    $

    2,029

     

    (a)

    Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, certain severance costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, interest income, other expense (income), net, equity compensation, and system conversion costs. Adjusted EBITDA is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income (loss) attributable to common stockholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

    (b)

    Income tax expense for the three months and year ended December 31, 2025 includes $29.4 million of expense related to the establishment of nonrecurring valuation allowances on the Company's deferred tax assets.

    (c)

    Acquisition and integration-related (income) costs are related to the Aya Merger, and include the Aya termination fee of $20.0 million paid by Parent to the Company in December 2025 upon Parent's termination of the Aya Merger Agreement, and associated fees paid by the Company in the fourth quarter of 2024 and throughout 2025.

    (d)

    Restructuring costs were primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives.

    (e)

    Severance costs - executive transition relates to the former Chief Executive Officer's separation from the Company in December 2025 and consists of various severance payments pursuant to the General Release executed December 31, 2025.

    (f)

    Includes legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations. The Company incurred a settlement expense of $1.2 million, and recorded a $1.8 million recovery related to a previous loss, in the fourth quarter of 2024, and incurred $19.4 million of credit loss expense, driven by a bankruptcy filing by a single MSP customer, for the year ended December 31, 2024.

    (g)

    Impairment charges for the three months and year ended December 31, 2025 included non-cash goodwill impairment charges related to the Company's Nurse and Allied and Physician Staffing segments, primarily triggered by the fourth quarter decline in the Company's equity market capitalization. Impairment charges for the year ended December 31, 2024 primarily related to right-of-use assets and related property in connection with vacated leases during 2024, as well as the write-off of goodwill and intangible assets associated with the impairment of a previous asset acquisition.

    (h)

    System conversion costs include enterprise resource planning system costs related to the upgrading and integrating of our middle and back-office platforms, with certain development costs capitalized and amortized in accordance with the Company's policies.

    (i)

    Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related (benefits) costs, restructuring (benefits) costs, certain severance costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, system conversion costs, and nonrecurring income tax adjustments. Adjusted EPS is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes Adjusted EPS provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company than EPS. Quarterly non-GAAP adjustment may vary due to rounding.

    (j)

    Nonrecurring income tax adjustment for the three months and year ended December 31, 2025 includes $29.4 million of expense related to the establishment of nonrecurring valuation allowances on the Company's deferred tax assets.

    (k)

    Segment data is provided in accordance with the Segment Reporting Topic of the Financial Accounting Standards Board Accounting Standards Codification.

    (l)

    Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other (gains) losses, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

    (m)

    Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and Company-wide projects (initiatives).

    (n)

    Legal and other losses (gains) include legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations.

    (o)

    Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.

    (p)

    FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

    (q)

    Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.

    (r)

    Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by eight hours.

    (s)

    Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260303192399/en/

    Cross Country Healthcare, Inc.

    William J. Burns, 561-237-2555

    Executive Vice President & Chief Financial Officer

    wburns@crosscountry.com

    Get the next $CCRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCRN

    DatePrice TargetRatingAnalyst
    3/19/2026$15.00Neutral → Outperform
    Wedbush
    3/5/2026$14.00Hold → Buy
    The Benchmark Company
    2/3/2026$11.00Neutral
    Wedbush
    12/4/2025$11.00Mkt Perform → Mkt Outperform
    Citizens JMP
    12/10/2024Outperform → Mkt Perform
    Barrington Research
    12/6/2023Mkt Perform
    JMP Securities
    11/3/2023$32.00 → $21.00Buy → Hold
    Jefferies
    6/26/2023Outperform
    William Blair
    More analyst ratings

    $CCRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Krug Marc S.

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    4/2/26 4:10:01 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    SEC Form 4 filed by Hawkins Amiee Lin

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    4/2/26 4:09:43 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    SEC Form 4 filed by Clark Kevin Cronin

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    4/2/26 4:08:19 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $CCRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cross Country upgraded by Wedbush with a new price target

    Wedbush upgraded Cross Country from Neutral to Outperform and set a new price target of $15.00

    3/19/26 8:22:53 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Cross Country upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Cross Country from Hold to Buy and set a new price target of $14.00

    3/5/26 8:22:11 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Wedbush initiated coverage on Cross Country with a new price target

    Wedbush initiated coverage of Cross Country with a rating of Neutral and set a new price target of $11.00

    2/3/26 8:08:13 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $CCRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cash W Larry bought $40,829 worth of shares (5,000 units at $8.17), increasing direct ownership by 3% to 204,632 units (SEC Form 4)

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    12/9/25 4:08:59 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Director Cash W Larry bought $61,320 worth of shares (6,000 units at $10.22), increasing direct ownership by 3% to 199,632 units (SEC Form 4)

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    12/31/24 5:15:10 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $CCRN
    SEC Filings

    View All

    SEC Form DEFR14A filed by Cross Country Healthcare Inc.

    DEFR14A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

    4/2/26 8:30:53 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    SEC Form DEF 14A filed by Cross Country Healthcare Inc.

    DEF 14A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

    3/30/26 5:29:49 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    SEC Form DEFA14A filed by Cross Country Healthcare Inc.

    DEFA14A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

    3/30/26 5:29:09 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $CCRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cross Country Healthcare and Open Hearts for Orphans Announce Community Partnership to Strengthen Families and Support Vulnerable Children

    Cross Country Healthcare, Inc. (NASDAQ:CCRN), a technology-driven healthcare workforce solutions company delivering an AI-powered digital platform and advisory services backed by nearly 40 years of healthcare labor expertise, today announced a new community partnership with Open Hearts for Orphans (OHFO), a South Florida nonprofit dedicated to providing hope, healing, and family for orphaned and vulnerable children. This partnership brings together two mission-driven organizations committed to strengthening families, supporting communities, and improving outcomes for vulnerable children and the caregivers who support them. Through this collaboration, Cross Country will support OHFO thro

    3/10/26 7:30:00 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Cross Country Healthcare Announces Fourth Quarter and Full Year 2025 Financial Results

    Cross Country Healthcare, Inc. (the "Company," "Cross Country," "we," "us," and "our") (NASDAQ:CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2025. SELECTED FINANCIAL INFORMATION: Dollars are in thousands, except per share amounts Q4 2025 Variance Q4 2025 vs Q4 2024 Variance Q4 2025 vs Q3 2025 Full Year 2025 Variance 2025 vs 2024 Revenue $ 236,761       (24 ) %   (5 ) % $ 1,054,293       (22 ) % Gross profit margin*   20.3   %   30

    3/4/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Cross Country Healthcare to Attend the Truist Securities Virtual Human Capital Conference and the Oppenheimer 36th Annual Healthcare Medtech & Services Conference

    Cross Country Healthcare, Inc. (the "Company") (NASDAQ:CCRN) announced today that it is scheduled to participate in two upcoming conferences: The Truist Securities Virtual Human Capital Conference taking place March 12-13, 2026, with one-on-one investor meetings on Thursday, March 12. The Oppenheimer 36th Annual Healthcare MedTech & Services Conference taking place March 16-19, 2026, with one-on-one investor meetings on Tuesday, March 17. In attendance and participating in one-on-ones at both conferences will be William J. Burns, Executive Vice President & Chief Financial Officer and Josh Vogel, Vice President, Investor Relations. No formal presentation will be made at either confe

    2/23/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $CCRN
    Leadership Updates

    Live Leadership Updates

    View All

    Cross Country Healthcare Announces CEO Transition

    Co-Founder and Chairman, Kevin C. Clark, Returns as Chief Executive Officer Cross Country Healthcare, Inc. (the "Company" and "Cross Country") (NASDAQ:CCRN) today announced that John A. Martins, the Company's President and Chief Executive Officer, has separated from the Company and ceased to serve as a member of its Board of Directors (the "Board"), effective as of December 14, 2025. The Board appointed Kevin C. Clark, the Company's current Chairman, former Chief Executive Officer, and Co-Founder, to succeed Mr. Martins as the Company's President and Chief Executive Officer. Mr. Clark will continue to serve as the Chairman of the Board. "The Board members are thrilled to have Kevin return

    12/15/25 8:15:00 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Aya Healthcare to Acquire Cross Country Healthcare for Approximately $615 Million in Cash

    Cross Country stockholders to receive $18.61 per share Expands Aya's client service and delivery capabilities with Cross Country's nearly 40-year history of clinical excellence and quality patient care Provides clinicians with greater flexibility and convenience by tapping into the combined pool of nationwide opportunities, with competitive compensation and a world-class experience Creates immediate stockholder value for Cross Country, through a nearly 67 percent premium Aya Healthcare and Cross Country Healthcare today announced that they have entered into a definitive agreement whereby Aya will acquire Cross Country for $18.61 per share in cash in a transaction valued at appr

    12/4/24 7:45:00 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

    NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

    9/26/24 6:04:00 PM ET
    $CCRN
    $CHK
    $ENSG
    Professional Services
    Consumer Discretionary
    Oil & Gas Production
    Energy

    $CCRN
    Financials

    Live finance-specific insights

    View All

    Cross Country Healthcare Announces Fourth Quarter and Full Year 2025 Financial Results

    Cross Country Healthcare, Inc. (the "Company," "Cross Country," "we," "us," and "our") (NASDAQ:CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2025. SELECTED FINANCIAL INFORMATION: Dollars are in thousands, except per share amounts Q4 2025 Variance Q4 2025 vs Q4 2024 Variance Q4 2025 vs Q3 2025 Full Year 2025 Variance 2025 vs 2024 Revenue $ 236,761       (24 ) %   (5 ) % $ 1,054,293       (22 ) % Gross profit margin*   20.3   %   30

    3/4/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Cross Country Healthcare to Hold Fourth Quarter and Full Year 2025 Earnings Conference Call on Wednesday, March 4, 2026

    Cross Country Healthcare, Inc. (NASDAQ:CCRN) will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026 at 5:00 P.M. Eastern Time. Cross Country Healthcare, Inc. (the "Company") intends to distribute its earnings press release after market close on Wednesday, March 4, 2026. This call will be webcast live and can be accessed at the Company's website at ir.crosscountry.com or by dialing 800-369-2163 from anywhere in the U.S. or by dialing 773-756-4715 from non-U.S. locations – Passcode: Cross Country. A replay of the webcast will be available from March 4th through March 18th on the Company's website and a replay of

    2/12/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Cross Country Healthcare Announces Third Quarter 2025 Financial Results

    Cross Country Healthcare, Inc. (the Company) (NASDAQ:CCRN) today announced financial results for its third quarter ended September 30, 2025. Selected Financial Information:     Variance Variance     Q3 2025 vs Q3 2025 vs Dollars are in thousands, except per share amounts Q3 2025 Q3 2024 Q2 2025 Revenue $ 250,052     (21 )%   (9 )% Gross profit margin*   20.4 %   — bps   — bps Net loss attributable to common stockholders $ (4,774 )   (287 )%

    11/12/25 4:56:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $CCRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cross Country Healthcare Inc.

    SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

    11/13/24 9:39:57 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Cross Country Healthcare Inc.

    SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

    11/13/24 4:36:10 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    SEC Form SC 13G/A filed by Cross Country Healthcare Inc. (Amendment)

    SC 13G/A - CROSS COUNTRY HEALTHCARE INC (0001141103) (Subject)

    2/13/24 5:02:31 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary